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WS21.1 Cystic ﬁbrosis incidence in Portugal
P. Pacheco1, C. Silva1, P. Loureiro1. 1Instituto Nacional de Sau´de Dr. Ricardo
Jorge, Gene´tica Humana, Lisboa, Portugal
Objectives: The incidence of Cystic Fibrosis (CF) in the European Caucasian
population is about 1 in 2500 live births and about 1 in 25 people are carriers of a CF
genetic mutation. These numbers were generally adopted, but there may be marked
regional variations. The p.Phe508del mutation is the most common mutation causing
CF. In central and northern Europe, this mutation has a frequency of about 70%.
But previously published data indicated that in Spain and Portugal the frequency
of this mutation was much lower, around 50%. To estimate the incidence of CF in
Portugal we have determined with high accuracy the frequency of the p.Phe508del
in our CF patients and calculate the incidence of the disease by determining the
incidence of CF carriers analysing consecutive new-borns.
Methods: A group of 509 CF patients, with extensive or complete CFTR gene
analysis (by DGGE and/or sequencing), was clinically revaluated and part of
the diagnostics were excluded. The frequency of the p.Phe508del mutation was
determined in the conﬁrmed CF cases as 66.4%±3.2% (95% CI). Then, we have
analysed 1603 Guthrie-cards and detected 26 p.Phe508del carriers, and a CF carrier
incidence of 2.44%±0.75% (95% CI) (sample size calculator). About 1 in 37 people
are CF carriers and the CF incidence is 1 in 5500.
Conclusion: The frequency of the p.Phe508del in Portuguese CF patients 66.4% is
similar to the French 67.2% and other European countries, but different from the
reported data of Spain 50.6%. The CF incidence in our population of 1 in 5500 is
much lower than expected, probably due to our population admixture.
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In the recent years, NIPD has found new applications in monogenic diseases
diagnostic for paternally inherited mutations. Such an approach remains very
challenging because of the inherent limitations of molecular testing methods, the
low concentration of circulating free fetal DNA (cff-DNA) in maternal plasma and
the “maternal contamination”.
We developed and evaluated an NIPD test for Cystic Fibrosis for the most common
French mutation. It consists in searching the paternal mutation in compound
heterozygous families using MEMO-PCR method (Lee et al 2011) associated with
real-time PCR. The analytical validation step was made on chimeric DNA control
samples that contain 0%, 2%, 5%, 10%, 50% and 100% of mutant DNA at a ﬁnal
concentration of 100 pg/mL. In addition, we have assessed a mini STR kit as quality
control to conﬁrm the presence of cff DNA in the maternal plasma. We obtained
the ﬁrst proofs of concept of our approach by the accuracy for the detection of the
p.Gly542* mutation. Real-time MEMO PCR demonstrated the blocking efﬁciencies
of normal allele with an enrichment of mutant allele and reveals differences in
melting curve shape that correlate with the nature of each chimeric sample with
a detection threshold of 2%. A tri-allelic proﬁle was found for all tested maternal
plasma.
Our new approach offers numerous advantages: it is simple, cost and time ef-
ﬁcient, and applicable to different type of variants: point mutations or small
insertion/deletions. Therefore, this method does not require complex equipment
or bioinformatics setting and can be easily applicable in routine. Nevertheless
validation studies are necessary to be manageable in clinical practice.
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Objectives: D1152H is a IV class mutation causative of milder clinical manifesta-
tions in Cystic Fibrosis (CF). In order to assess the prevalence and clinical features
of patients (pts) with CF and D1152H mutation, we retrospectively evaluated a
cohort of patients in follow-up at 3 CF Centers.
Methods: We analyzed age and symptoms at diagnosis, sweat test chloride (ST),
sputum, radiological exams, pancreatic status, FEV1% predicted and complications
in 630 CF pts (mean age: 20.6 yrs, range 4 months-49 yrs). D1152H mutation
was detected in 20/630 pts (3.1%; mean age: 19.8 yrs, range 3−49 yrs); 14/20
were compound heterozygous for other CFTR causing mutations. Mean age at
diagnosis of this subset of pts was 12.6 yrs (range: 6 months-48 yrs). 3/20 were
diagnosed by neonatal screening, 6/20 by respiratory symptoms, 4/20 by infertility,
4/20 by familiarity, 2/20 by recurrent pancreatitis and 1/20 by intestinal symptoms.
3/20 pts had pancreatic insufﬁciency. At diagnosis the ST was negative/borderline in
18/20 cases. 4/20 suffered from recurrent pancreatitis. 9/20 showed bronchiectasis,
only 5/20 have occasional Pseudomonas aeruginosa (PA) infections during the
follow up while 2/20 had chronic infection by PA. 6/20 suffered from complications
as chronic pancreatitis (1/20), hemoptysis (2/20), liver disease (2/20) and allergic
bronchopulmonary aspergillosis (1/20).
Conclusions: Although D1152H mutation is related to milder CF forms our results
show a variability of clinical symptoms, including early onset of lung disease. The
inclusion of D1152H mutation in screening panels could be recommended in order
to early perform therapeutic interventions.
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Idiopathic pancreatitis is a multigenic and multifactorial disease. Genetically deter-
mined pancreatitis is associated with PRSS1, SPINK1 and CFTR mutations.
This study aims at investigating clinical and morphological characteristics of pa-
tients diagnosed with genetically determined sporadic pancreatitis. Inclusion criteria
were the presence of PRSS1, CFTR or SPINK1 mutations in patients with idiopathic
or chronic pancreatitis. Patients with hereditary pancreatitis were excluded. Age-
and gender-matched patients with idiopathic pancreatitis and negative genetic testing
served as controls (n = 68).
Genetic testing was performed in 351 referrals to our centre since 1999. Of these,
61 (17.4%) carried at least one mutation (34 CFTR, 10 PRSS1 and 13 SPINK1),
while four showed a combination of mutations. Follow-up has been extended to a
median of 5 (range 1−40) years. Similar clinical features were noted in cases and
controls except for an earlier age of onset of pancreatic symptoms and a higher
incidence of pancreatic cancer in patients with CFTR mutations compared with
controls (p< 0.05). The ratio of observed to expected pancreatic cancers averaged
26.5 (95% CI: 8.6–61.9). All pancreatic cancer patients were smokers.
Except for an earlier age of onset of pancreatic disease, clinical features of patients
with sporadic idiopathic pancreatitis and gene mutations were similar to those of
controls. A signiﬁcantly higher occurrence of pancreatic cancer was observed in
patients carrying CFTR mutations. We therefore suggest including patients with
CFTR variants and risk factors into a screening and surveillance program, while
strongly advising them to stop smoking.
